C. C. Broder

Structure and design of Langya virus glycoprotein antigens

The paper determines the structure of Langya virus glycoproteins and shows they use a different receptor than NiV and HeV, with no cross-reactivity of antibodies.

The Sequence Basis for Selectivity of Ephrin-B2 Ligand for Eph Receptors and Pathogenic Henipavirus G Glycoproteins

This paper identifies sequence changes in Ephrin-B2 that enhance its binding to henipavirus glycoproteins over Eph receptors, enabling the design of neutralizing decoy receptors.

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.

Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection

This study examines SARS-CoV-2-specific T cell responses 12-months post-infection, finding durable responses with higher frequencies in those with severe acute illness.

Functional cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein

This study identifies human monoclonal antibodies that neutralize HeV and NiV by targeting distinct antigenic sites on the receptor binding protein and demonstrates their cooperative binding and synergistic therapeutic effects.

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein

The paper reports the high-resolution structure of the SARS-CoV-2 Spike RBD and identifies a conserved epitope accessible in open conformations, which is targeted by cross-reactive antibodies.